2023 World Conference on Lung Cancer (Posters)-P2.31. Determining Lines of Therapy in Patients with Metastatic Non-Small Cell Lung Cancer Using Real-World Data

P2.31. Determining Lines of Therapy in Patients with Metastatic Non-Small Cell Lung Cancer Using Real-World Data - PDF(Slides)

Back to course

Pdf Summary

Determining the lines of therapy (LOT) for patients with metastatic non-small cell lung cancer (mNSCLC) using real-world data is important for accurate analysis. However, existing rules for determining LOT do not consider the use of targeted therapies in current treatments. In this study, the authors aimed to develop rules for determining LOT based on real-world data of patients with mNSCLC treated with targeted therapies.<br /><br />The study included 1,133 patients with EGFR mNSCLC and a total of 3,168 treatment regimens. After applying the developed rules, 2,834 LOTs were determined. The authors found that 11% of regimen changes were prevented from advancing the LOT according to the rules.<br /><br />The developed rules for determining LOT included criteria such as the introduction of agents within a certain time frame, the use of angiogenesis inhibitors, and the gap between prior and current regimens. Different rules were applied for the same agent, interchangeable agents, and non-interchangeable agents.<br /><br />The rules were initially created based on expert consensus and review of real-world treatment records of patients with ALK or ROS1 mNSCLC. They were then modified and applied to an independent cohort of patients with EGFR mNSCLC to validate their use.<br /><br />The study used real-world data from 12 North American institutions participating in the Academic Thoracic Medical Investigator’s Consortium (ATOMIC). The developed rules for determining LOT were able to account for the increased use of targeted therapies in patients with mNSCLC.<br /><br />Overall, this study proposes six rules for determining LOT from real-world treatment records, taking into account the use of targeted therapies. The rules provide a framework for evaluating current treatment patterns in patients with mNSCLC and can help improve the accuracy of analyses using real-world data.

Asset Subtitle

Melina Marmarelis

Meta Tag

Speaker Melina Marmarelis

Topic Global Health, Health Services & Health Economics: Real World Data

Keywords

lines of therapy

metastatic non-small cell lung cancer

real-world data

targeted therapies

EGFR mNSCLC

treatment regimens

regimen changes

angiogenesis inhibitors

expert consensus

ALK or ROS1 mNSCLC